Search for Clinical Trial Results
Indolent B Cell Lymphoma - 25 Studies Found
Status | Study |
Completed |
Study Name: Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Condition: Lymphoma, Non-Hodgkin Date: 2009-07-30 Interventions: Biological: tositumomab and Iodine I 131 tositumomab (anti-B1 antibody) For the treatment of 1st or 2nd |
Active, not recruiting |
Study Name: Bortezomib and Romidepsin in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Indolent B-cell Lymphoma, Peripheral T-cell Lymphoma or Cutaneous T-Cell Lymphoma Condition:
Date: 2009-08-20 Interventions:
|
Active, not recruiting |
Study Name: Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 Condition: Leukemia Date: 2007-04-25 Interventions:
|
Terminated |
Study Name: A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas Condition:
Date: 2008-10-06 Interventions: Drug: AEG35156 antisense IV infusion AEG35156 will be give |
Active, not recruiting |
Study Name: A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies Condition:
Interventions: Drug: DI-B4 DI-B4 will be administered once weekly for up to a total of four weeks. The starting dose wi |
Active, not recruiting |
Study Name: Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma Condition:
|
Recruiting |
Study Name: Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma Condition:
|
Completed |
Study Name: Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma Condition: Lymphoma Date: 2004-10-06 Interventions: Drug: bortezomib + rituximab Arm I: Patients receive borte |
Completed |
Study Name: Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma Condition: Lymphoma Date: 2005-11-22 Interventions:
|
Completed |
Study Name: Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma Condition: Lymphoma Date: 2000-01-21 Interventions:
|